aminopeg36conhpeg36acid

GLP-1(7-36) amide (MKC 253) is a peptide hormone released from intestinal L-cells upon nutrient intake. It binds to the GLP-1 receptor in the pancreas, enhancing insulin secretion from pancreatic β-cells and increasing insulin expression, thereby exhibiting antidiabetic effects.

GLP-1(32-36)amide acetate is a pentapeptide and derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide acetate could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

RS09 2TFA (1449566-36-2 free base) is a TLR4 agonist. Promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. It acts as an adjuvant in vivo and enhances X-15 specific antibody serum concentrations.

GLP-1(28-36)amide acetate inhibits mitochondrial permeability transition with antioxidant, anti-diabetic and cardioprotection activities.

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)), is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a 16-1 expression.

antagonist at the human GLP-1 receptor

GLP-1(32-36)amide TFA, a pentapeptide derived from the C-terminal end of the glucoregulatory hormone GLP-1, has demonstrated the ability to mitigate weight gain and regulate glucose metabolism in diabetic mice [1] [2].

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

Hen egg-white lysozyme has a molecular weight of about 14,600 and each molecule comprises 129 amino acid residues1. The activity of lysozyme in promoting the dissolution of bacterial cell walls is now known to depend upon its ability to catalyze the hydro

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Peptide YY (PYY) (3-36), human trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64716.

GLP-1(7-36), amide TFA is a prominent intestinal hormone that stimulates glucose-induced insulin secretion from β cells[1].

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is an important compound that functions as an antioxidant primarily targeting the mitochondrion to inhibit mitochondrial permeability transition (MPT), displaying anti-diabetic properties and cardioprotection effects[1].

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide biotinylated at the C-terminal.

Apelin-36(human) TFA, an endogenous agonist of the orphan G protein-coupled receptor APJ, exhibits a potent EC50 of 20 nM and high affinity (pIC5 50 = 8.61) for human APJ receptors in HEK 293 cells. It is involved in significant cardiovascular and metabolic activities. Furthermore, Apelin-36(human) TFA can inhibit the entry of certain HIV-1 and HIV-2 strains into NP2/CD4 cells expressing the APJ receptor. [1] [2] [3] [4]

Apelin-36(rat, mouse) TFA, an endogenous agonist for the orphan G protein-coupled receptor APJ, exhibits a strong affinity for APJ receptors with an IC 50 of 5.4 nM and effectively inhibits cAMP production with an EC 50 of 0.52 nM. Moreover, it obstructs the invasion of certain HIV-1 and HIV-2 strains into NP-2/CD4 cells that express the APJ receptor [1] [2].

Endogenous APJ receptor agonist (EC50 = 20 nM) that is secreted by adipocytes. Binds with high affinity to human APJ receptors expressed in HEK 293 cells (pIC50= 8.61). Involved in regulation of cardiovascular function, fluid homeostasis and feeding. Bloc

JV-1-36, a growth hormone-releasing hormone (GHRH) antagonist, suppresses reactive oxygen species production in A549 lung cancer cells and serves as a research tool to investigate GHRH antagonists' effects in vitro [1].

GLP-1 (1-36) amide (human, rat) is a molecular variant of the GLP-1 (7-36) amide and has the capacity to stimulate [14C]aminopyrine accumulation in enzymatically dispersed, enriched rat parietal cells [1].

(Ser8)-GLP-1 (7-36) amide, human, is a glucagon-like peptide-1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. This entero-insulinotropic hormone promotes glucose-dependent insulin secretion from pancreatic β-cells and affects gastrointestinal motility and secretion [1].

'(Tyr36)-pTH-Related Protein (1-36) (human, mouse, rat), a peptide, functions as a ligand for parathyroid hormone (PTH) receptors [1].'

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).

Galanin (1-13)-Neuropeptide Y (25-36) amide exhibits high-affinity binding to galanin receptors, comparable to that of galanin itself [1].

Peptide YY (PYY) (3-36), human (TFA) is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite[1].

GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

Protein Kinase C (19-36) is a pseudosubstrate peptide that inhibits protein kinase C (PKC) with an IC50 of 0.18 μM.

Human PTHrP-(1-36) is a secreted parathyroid hormone-related protein with anticalciuric effects, promoting beta cell function and proliferation, and is used in research on humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism [1] [3].

Neuropeptide Y (3-36) (porcine) acts as an agonist for the Y2 subtype of the neuropeptide Y (NPY) receptor, effectively stimulating feeding behavior in rats. This compound exhibits high selectivity for the Y2 receptor compared to the non-selective Y1 Y2 receptor ligand, Neuropeptide Y 1-36 [1][2][3].

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide known for its antidiabetogenic properties, including enhancing insulin secretion [1] [2].

GLP-1 (1-36) amide (human, rat) TFA, a variant of GLP-1 (7-36) amide, induces [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4) and is known as a selective Y2 receptor agonist, effectively reducing the release of norepinephrine via the Y2 receptor [1][2].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

Peptide YY (PYY) (3-36), porcine TFA, acts as a gut hormone and Y2 receptor agonist, effectively reducing appetite [1].

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), is an antioxidant that targets mitochondria and inhibits mitochondrial permeability transition (MPT), demonstrating anti-diabetic and cardioprotective effects [1].

Neuropeptide Y (22-36), a 15-amino-acid peptide, is a fragment of Neuropeptide Y (NPY), a 36-amino-acid neuropeptide involved in various physiological and homeostatic processes in the central and peripheral nervous systems. NPY, the most abundant peptide in the mammalian central nervous system, is secreted alongside neurotransmitters such as GABA and glutamate.

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

Neuropeptide Y (2-36) (porcine) is a pig-sourced peptide closely resembling its rat and human counterparts with 97.14% homology. It acts as an agonist for rat neuropeptide receptors Y5, Y2, and Y1, with EC50 values of 1.2, 1.6, and 3.4 nM, respectively. This compound is utilized in research on obesity and eating disorders [1].

Neuropeptide Y (18-36) (porcine) acts as a competitive antagonist of the neuropeptide Y (NPY) cardiac receptor, blocking I-NPY attachment to cardiac ventricular membranes. Its concentration-dependent action has an IC50 value of 158 nM and a Ki value of 140 nM. This compound is utilized in studying congestive heart failure [1].

Amyloid β-Protein (36-42), the 36-42 fragment of β-Amyloid, consists of a polypeptide chain of 36-43 amino acids and is a primary constituent of amyloid plaques in Alzheimer's disease (AD) patients' brains. β-Amyloid oligomers (Aβos) critically contribute to AD progression by causing neuronal harm and cognitive decline [1].

Peptide YY (13-36) (canine, mouse, porcine, rat) is a Y2 receptor subtype agonist [1].

GLP-1(32-36)amide is a pentapeptide compound derived from the C terminus of the glucoregulatory hormone GLP-1. This compound has shown potential in inhibiting weight gain and regulating glucose metabolism in diabetic mice[1][2].

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Endogenous APJ receptor agonist that is secreted by adipocytes. Binds with high affinity to APJ receptors (IC50 = 5.4 nM) and potently inhibits cAMP production in vitro (EC50 = 0.52 nM). Involved in regulation of cardiovascular function, fluid homeostasis